The startup is developing a kind of macrocyles, which share strengths of both small molecules and biologics, to make oral ...

By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to Alnylam’s future.

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

AbbVie will pay $200 million to acquire privately held Nimble Therapeutics and its pipeline of oral peptide drugs for immune diseases like psoriasis and inflammatory bowel disease, the pharmaceutical ...

Regeneron Pharmaceuticals intends to advance two blood-thinning drugs into Phase 3 testing next year after mid-stage study results showed they matched or surpassed marketed medicines at preventing ...

Dec. 31, 2024 – Jan. 22, 2025 • New York, New York ...

Dec. 24, 2024 – Dec. 31, 2024 • New York, New York ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.

Industry experts said profit pressure and M&A contributed to job losses. They said layoffs will likely persist in 2025, but ...